| ²é¿´: 801 | »Ø¸´: 2 | |||
| ¡¾ÐüÉͽð±Ò¡¿»Ø´ð±¾ÌûÎÊÌ⣬×÷Õßwfpzmd360073½«ÔùËÍÄú 30 ¸ö½ð±Ò | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
wfpzmd360073½ð³æ (СÓÐÃûÆø)
|
[ÇóÖú]
ÎÄÏ×ÇóÖú£¬¼±¼±¼±£¡£¡£¡£¡ ÒÑÓÐ1È˲ÎÓë
|
||
|
ÇóÖúһƪÁÙ´²Ñо¿ÎÄÕ£¬Â·¹ýµÄ´óÉñÇë°ï棬лл£¡£¡£¡£¡ Á´½Ó£ºhttps://pubmed.ncbi.nlm.nih.gov/38823410/ doi: 10.1016/S1470-2045(24)00159-1. Epub 2024 May 29 ÌâÄ¿£ºBL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study |
» ²ÂÄãϲ»¶
ºÓ±±Ò½¿Æ´óѧҩѧÏà¹Ø×¨Òµ½ÓÊܵ÷¼Á
ÒѾÓÐ20È˻ظ´
ÄÔ¹£ÔõôÖÎÁÆ
ÒѾÓÐ3È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ72È˻ظ´
ÄÔ¹£ÔõôÖÎÁÆ
ÒѾÓÐ0È˻ظ´
ÉúÎï×éÖ¯ÖÐÓÐÄ¿±ê·ÖÎöÎרÊôÐÔÔõô×ö
ÒѾÓÐ0È˻ظ´
¡¾ÕÐÆ¸¡¿Ç廪´óѧҩѧԺǮ·æ½ÌÊÚ¿ÎÌâ×é³ÏƸ²©Ê¿ºó
ÒѾÓÐ1È˻ظ´
аæscifinder
ÒѾÓÐ1È˻ظ´
°²½ÝÂ×ÒºÏàÉ«Æ×ÖùÓë·½·¨¿ª·¢Ö¸ÄÏ
ÒѾÓÐ4È˻ظ´
2026ÉêÇ뿼ºË²©Ê¿×Ô¼ö-µ°°×ÖÊ×éѧ/AI/Ò©ÎïÉè¼Æ/AIDD/»¯Ñ§ÉúÎïѧ
ÒѾÓÐ1È˻ظ´

tfang
ľ³æÖ®Íõ (ÎÄ̳¾«Ó¢)
ľ³æ008Ö®´óÀÁ³æ
- Ó¦Öú: 107 (¸ßÖÐÉú)
- ¹ó±ö: 0.002
- ½ð±Ò: 106579
- É¢½ð: 8512
- ºì»¨: 129
- ɳ·¢: 3
- Ìû×Ó: 43508
- ÔÚÏß: 1950Сʱ
- ³æºÅ: 529162
- ×¢²á: 2008-03-20
- ÐÔ±ð: GG
- רҵ: ÂÌÉ«Óлú»¯Ñ§
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
|
ͨ¹ýÍøÅÌ·ÖÏíµÄÎļþ£ºBL-B01D1, a first-in-class EGFR¨CHER3 bispecific antibody¨Cdrug conjugate, in patients with locally advanced or metastatic solid tumours a first-in-human, open-label, multicentre, phase 1 study._20251127_083531.pdf Á´½Ó: https://pan.baidu.com/s/1Fjp97hdJLNbLM_NIE6nOHQ?pwd=bpib ÌáÈ¡Âë: bpib ¸´ÖÆÕâ¶ÎÄÚÈݺó´ò¿ª°Ù¶ÈÍøÅÌÊÖ»úApp£¬²Ù×÷¸ü·½±ãŶ |

3Â¥2025-11-27 08:35:43
zyqchem
ľ³æÖ®Íõ (ÎÄѧ̩¶·)
- Ó¦Öú: 158 (¸ßÖÐÉú)
- ½ð±Ò: 282018
- ºì»¨: 551
- ɳ·¢: 1958
- Ìû×Ó: 54692
- ÔÚÏß: 11741.5Сʱ
- ³æºÅ: 3786654
- ×¢²á: 2015-04-04
- רҵ: ºÏ³ÉÒ©Îﻯѧ
2Â¥2025-11-26 12:01:26













»Ø¸´´ËÂ¥
5